Toggle navigation
Menu
About Us
Investment Strategy
Team
Portfolio
News
Contact Us
Limited Partners
Portfolio
Symphogen A/S
Develops recombinant antibody mixtures for the treatment and prevention of disease
Ballerup, Denmark
Contact:
Acquisition
Acquired by: Servier
Related News
Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology
Symphogen and Open Monoclonal Technology Announce Collaboration
Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGa
Symphogen Welcomes Four New Board Members
Symphogen Raises €100 Million in Private Equity Round
Symphogen Issued United States Patent Covering Symplex™ Technology for Antibody Discovery
